A systematic analysis of biotech startups that went public in the first half of 2021
| Autor: | Huayamares, Sebastian G., Lokugamage, Melissa P., Sanchez, Alejandro J. Da Silva, Dahlman, James E. |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | 2022 Current Research in Biotechnology |
| Druh dokumentu: | Working Paper |
| DOI: | 10.1016/j.crbiot.2022.09.004 |
| Popis: | Biotechnologies are being commercialized at historic rates. In 2020, 74 biotech startups went public through an Initial Public Offering (IPO), and 60 went through the IPO process in the first six months of 2021. However, the traits associated with biotech startups obtaining recent IPOs have not been reported. Here we build a database of biotechs that underwent an IPO in the first half of 2021. By analyzing leadership, technological focus, clinical trials, and financing, we found that advanced degrees among the leadership, clinical trials, and intellectual property are important factors for biotech startups. The data also suggest that large private rounds can decrease time-to-IPO and affect post-IPO stock performance. Notably, these traits were often exhibited by the 138 biotech IPOs in 2018-2019, suggesting 2021 data were not driven by COVID. Comment: 14 Pages main text, 6 Pages of Supplementary Info , 6 Figures, 4 Supplementary Figures |
| Databáze: | arXiv |
| Externí odkaz: |
|